FDA to Collect $1.2 Billion in User Fees

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

WASHINGTON-President Bush has signed legislation that reauthorizes the Prescription Drug User Fee Act (PDUFA), first enacted in 1992 to speed up the FDA’s processing of new drug applications. PDUFA III is the second 5-year

WASHINGTON—President Bush has signed legislation that reauthorizes thePrescription Drug User Fee Act (PDUFA), first enacted in 1992 to speed up theFDA’s processing of new drug applications. PDUFA III is the second 5-yearextension. It authorizes collection of $1.2 billion in user fees in the next 5years from companies submitting NDAs.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content